Mysa Saad: Antiplatelets Increase Bleeding Without Reducing VTE in Cancer Patients
Mysa Saad, Internal Medicine Resident shared a post on LinkedIn about a recent article she and her colleagues co-authored, adding:
”Our new study published in Thrombosis Research:
In ambulatory patients with cancer on apixaban thromboprophylaxis:
- Concurrent antiplatelet/NSAID use increases clinically relevant bleeding (HR 1.80)
- Antiplatelets were the main driver of increased bleeding risk (HR 2.02)
- NSAIDs did not have a significant impact on bleeding risk
- No significant reduction in VTE
These results highlight the need to carefully reassess indications for concurrent antiplatelet agents/NSAIDs when considering apixaban thromboprophylaxis in patients with cancer.”
Title: Impact of concurrent antiplatelet use on the safety and efficacy of thromboprophylaxis with apixaban in patients with cancer: A post-hoc analysis of the AVERT trial
Authors: Mysa Saad, Tzu-Fei Wang, Ranjeeta Mallick, Danny Hill, Alejandro Lazo-Langner, Vicky Tagalakis, Philip S. Wells, Marc Carrier
Stay updated on all scientific advances with Hemostasis Today.
-
Oct 15, 2026, 19:41Looking Beyond Platelet Counts to Quality of Life in ITP – American Society of Hematology
-
Oct 15, 2026, 19:32Markus Gregorio Barbosa: Hepatic VPS35 and Cholesterol Homeostasis
-
Oct 15, 2026, 19:18Emerging Novel Therapies for Hereditary Hemorrhagic Telangiectasia – The Lancet Haematology
-
Oct 15, 2026, 19:04Umberto Pensato: EVT Treatment Effects Across Perfusion Profiles in MeVO Stroke
-
Oct 15, 2026, 18:26Chanakya Nayudu: Presenting My Research at ISTH Congress 2026 in Paris
-
Oct 15, 2026, 18:09Maha Othman: Students Lead World Thrombosis Day 2026 Awareness Events
-
Oct 15, 2026, 17:52Jill de Mol։ Rapamycin Modulates Immune Responses in Aged Atherosclerosis
-
Oct 15, 2026, 17:41Victor Aboyans։ Think About Lipids in VTE
-
Oct 15, 2026, 17:08Babu Mia։ Targeting PPM1D to Eliminate Malignant Stem Cells in Myeloproliferative Neoplasms